Oncology clinical trials at Murdoch

The Murdoch Oncology Clinical Trial Unit was established in 2012, with the aim of providing West Australian oncology patients and their families the best possible care through research-driven practice. Our current portfolio of trials examine outcomes of conventional and innovative cancer treatments.

  • Cancer is the leading cause of death in Australia, about one in two Australian men and one in three Australian women will be diagnosed with cancer by the age of 85.
  • Clinical trials play an essential role in discovering new and more effective treatments for cancer.
  • Great strides are being made in understanding cancer and we are working every day to achieving better quality and quantity of life for patients.
  • Providing exceptional care to patients by offering innovative cancer treatment which may only be available in a clinical trial setting.
  • Conducting clinical trials for patients having treatment for a range of cancer types including lung, breast, colorectal and upper gastrointestinal cancer.
  • Continual improvement of clinical trial processes and alignment with contemporary best practice.

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer.


PI: Dr Kynan Feeney

Sponsor: Bristol-Myers Squibb

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)


PI: Dr Kynan Feeney

Sponsor: Bristol-Myers Squibb

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer.


PI: Dr Raj Tota

Sponsor:  BeiGene

CA001-050 (BMS)
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer


PI: Dr Raj Tota

Sponsor:  Bristol-Myers Squibb

A Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer


PI: Dr Sanjay Mukhedkar

Sponsor: Janssen-Cilag

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer


PI: Dr Sanjay Mukhedkar

Sponsor: PharmaMar

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment


PI: Dr Raj Tota

Sponsor: AstraZeneca

A Study of Lazertinib and Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer


PI: Dr Raj Tota

Sponsor: Janssen-Cilag


Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel


PI: Dr Kynan Feeney

Spnsor:  NovoCure Ltd

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer


PI: Dr Kynan Feeney

Sponsor: Panbela Therapeutics

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression


PI: Dr Kynan Feeney

Sponsor: Amgen


Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive Triple Negative Breast Cancer


PI: Dr Daphne Tsoi

Sponsor:  OBI Pharma


A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer


PI: Dr Sanjay Mukhedkar

Sponsor:  Bristol-Myers Squibb


A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer


PI: Dr Kynan Feeney

Sponsor:  Bristol-Myers Squibb


A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression


PI: Dr Kynan Feeney

Sponsor: Amgen

Associate Professor Kynan Feeney - Medical Oncologist
Associate Professor Daphne Tsoi - Medical Oncologist
Dr Sanjay Mukhedkar - Medical Oncologist
Dr Raj Tota – Medical Oncologist
Rebecca Weselman – Clinical Trials Regulatory & Quality Officer
Sabina Jelinek - Clinical Trials Nurse 
Tijana Coe - Clinical Trial Co-ordinator
Shelby Margolius - Clinical Trial Co-ordinator
Diane DeVilla - Clinical Trial Co-ordinator
Tina Kern – Clinical Trials Support Officer
Kaiting Leong - Clinical Trials Pharmacist
Stella Wong - Clinical Trials Pharmacist
Paz-Ares LG, Ciuleanu TE, Cobo-Dols M, Bennouna J, Cheng Y, Mizutani H, Lingua A, Reyes F, Reinmuth N, De Menezes JJ, Jassem J, Protsenko S, Feeney K, et al. (2022) First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. Journal of Clinical Oncology 40 Suppl 17, LBA9026-LBA9026. DOI:10.1200/JCO.2022.40.17_suppl.LBA9026

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. (2022) Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature. Mar 23. DOI: 10.1038/s41586-022-04508-4.

Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, et al. (2022) First-line Nivolumab plus Ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, Phase 3 CheckMate 227 Part 1 trial. Journal of Thoracic Oncology 17, 289-308. DOI: 10.1016/j.jtho.2021.09.010.

Janjigian Y, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,  Bragagnoli AC, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R,  Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, et al. (2021) First-line Nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294), 27-40., DOI: 10.1016/S0140-6736(21)00797-2.

Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, CheckMate 577 Investigators et al. (2021) Adjuvant Nivolumab in resected esophageal or gastroesophageal junction cancer. New England Journal of Medicine 384, 1191-1203. DOI: 10.1056/NEJMoa2032125.

De Marinis F, Laktionov K, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino M, Metro G, Gottfried M, Tsoi D, et al. (2021) Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer. 152, 127-134. DOI: 10.1016/j.lungcan.2020.12.011.

Chan A, Lomma C, Chih H, Blackely E, Woodward N, Tsoi D, et al. (2021) Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. Asia-Pacific Journal of Clinical Oncology. 17, e70-e76. DOI: 10.1111/ajco.13576.

Wainberg ZA, Feeney K, Lee MA, Muñoz A, Gracián AC, Lonardi S, Ryoo BY, Hung A, Lin Y, Bendell J, Hecht JR. (2020) Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer 20, 633. DOI: 10.1186/s12885-020-07110-x.

Clarke SJ, Burge M, Feeney K, Gibbs P, Jones K, Marx G, Molloy MP, Price T, et al. (2020) The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS One, 15, e0229900. DOI:10.1371/journal.pone.0229900

Feeney K, Kelly R, Lipton L, Chao J, Acosta-Rivera M, Earle D, Lei M, Kollia G, Tebbutt N. (2019) CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology. 37, 15_suppl. DOI: 10.1200/JCO.2019.37.15_suppl.TPS4143

Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, et al. (2019). Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. European Journal of Cancer 116, 137-147. DOI:10.1016/j.ejca.2019.05.008.

Hart NH, Galvão DA, Saunders C, Taaffe DR, Feeney KT, Spry NA, Tsoi D, et al. (2018) Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. Trials 19, 695. DOI: 10.1186/s13063-018-3091-8.

Clarke SJ, Burge ME, Feeney KT, Jones K, Gibbs P, Molloy MP, Marx GM, Price TJ, Reece W, Segelov E,. Tebbutt NC. (2018) The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab. Journal of Clinical Oncology 36 Suppl 4, 719-719

Moehler M, Janjijian J, Adenis A, Aucoin J, Boku N, Chau I, Cleary I, Feeney K, et al. (2017) CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer. Journal of Clinical Oncology: 35, (suppl. TPS4132).

Hart NH, Newton RU, Spry NA, Taaffe DR, Chambers SK, Feeney KT, Joseph DJ, Redfern AD, Ferguson T, Galvão DA. (2017). Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy. BMJ Open. 0:e014458. DOI:10.1136/bmjopen-2016-014458